

Dostarlimab GARNET

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



Not qualified for an ESMO-MCBS credit



#### Serious and disabling adverse effects



#### Other adjustments



Dostarlimab GARNET

### SCORE

#### CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE



Overall Survival




Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Gynaecological Malignancies

Therapeutic Indication: Treatment of adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer that have progressed on or following prior treatment with a platinum-containing regimen

Experimental Arm: Dostarlimab

Control Arm: Single arm (Phase I)



